RecruitingOBSERVATIONAL

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

This study is investigating a medication called cabozantinib for adults who have neuroendocrine tumours (NETs). These are a type of cancer that can appear in different parts of the body. All participants in this study have already had at least one other treatment for their cancer, but it has unfortunately continued to grow. The study will take place in hospitals and clinics in Germany and Austria. About 150 people taking cabozantinib as part of their normal care will be involved. Doctors will collect information from their usual check-ups, tests, and scans to see how their cancer responds to the treatment, how long they stay on the medicine, and if they experience any side effects. Researchers will also look at how the treatment impacts their quality of life. This is an observational study, meaning no extra tests beyond standard care are needed.

At a glance

Status

Recruiting

Sponsor

Ipsen

Enrolment target

150

Start

17 Dec 2025

Estimated completion

31 Dec 2028

Neuroendocrine Tumors

What is this study about?

This research study is looking into a medicine called cabozantinib, specifically for adults who have a type of cancer known as neuroendocrine tumours (NETs). These tumours can develop in various places throughout the body. The people joining this study have already tried at least one other treatment for their cancer, but it has unfortunately continued to progress. The main goal is to understand how well cabozantinib works for these patients and how safe it is.

This study will take place in hospitals and clinics in Germany and Austria. Doctors will be following about 150 patients who are already taking cabozantinib as part of their routine care. They will collect information from regular appointments, blood tests, and scans that patients would have anyway. This helps them see how the cancer responds to the treatment, how long people continue to take cabozantinib, and if there are any side effects. They also want to understand if the treatment affects patients' daily lives and well-being.

It's important to know that this is an "observational study." This means that participants won't have any extra tests, procedures, or medicines specifically for the study. Everything doctors collect is part of the normal care patients would receive for their condition. This type of study helps gather valuable information about how treatments work in real-world settings.

Key takeaways

The study looks at cabozantinib for neuroendocrine tumours (NETs).
Participants have already tried other cancer treatments.
It's an 'observational study', using information from standard care.
Doctors will check how well cabozantinib works and its side effects.
It aims to understand real-world use of the medicine.
No extra tests or procedures are involved beyond your usual care.

Who may be eligible?

To be able to take part in this study, you must be 18 years old or older and have agreed to take part. You must also have decided with your doctor to start treatment with cabozantinib for your neuroendocrine tumours (NETs) before officially joining the study.

Your NET must be of a specific type (either pancreatic or extra-pancreatic, and 'well-differentiated') and considered incurable by surgery or to have spread to other parts of your body. You also need to have received at least one other whole-body treatment for your cancer in the past, not including somatostatin analogue medicines.

You would not be able to join this study if you are currently taking part in another clinical trial where you try a new treatment, or if you've done so in the last three months. Also, if there are medical reasons why you shouldn't take cabozantinib, based on its official instructions, you wouldn't be able to join.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you and your doctor already decided to start treatment with cabozantinib for your NETs?
Have you received at least one other whole-body cancer treatment in the past (excluding somatostatin analogues)?
Is your NET considered inoperable or has it spread to other parts of your body?
Are you not currently in another clinical trial where you're trying a new medicine?

Answer every question to see your result.

What does participation involve?

If you join this study, you won't have any extra visits, tests, or procedures beyond what your doctor would normally recommend for your care. You will continue to take cabozantinib as prescribed by your doctor. The study team will simply collect information from your routine hospital and clinic visits, including results from your regular medical check-ups, blood tests, and scans. They will also note any side effects you experience and how the treatment affects your overall well-being. There isn't a fixed total duration for your participation; it will depend on how long your doctor decides you should continue taking cabozantinib as part of your normal treatment.

Potential risks and benefits

Potential benefits of participating include helping researchers understand more about how cabozantinib works for neuroendocrine tumours, which could help future patients. Because this is an observational study, you will not be exposed to any additional risks beyond those associated with your standard medical care and the cabozantinib treatment itself, which your doctor will discuss with you. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (34)

Medizinische Universitaet Graz
Verified postcode
Graz, Austria· Not yet recruiting
Kepler Universitaetsklinikum GmbH Linz
Verified postcode
Linz, Austria· Not yet recruiting
Medizinische Universität Wien
Verified postcode
Vienna, Austria· Recruiting
MVZ am Klinikum Aschaffenburg
Verified postcode
Aschaffenburg, Germany· Not yet recruiting
Charité - Universitaetsmedizin Berlin
Verified postcode
Berlin, Germany· Recruiting
DRK Kliniken Berlin
Verified postcode
Berlin, Germany· Not yet recruiting
Evangelische Lungenklinik Berlin
Verified postcode
Berlin, Germany· Recruiting
Krankenhaus St. Joseph-Stift Bremen GmbH
Verified postcode
Bremen, Germany· Recruiting
Klinikum Chemnitz
Verified postcode
Chemnitz, Germany· Not yet recruiting
MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
Verified postcode
Cologne, Germany· Not yet recruiting
pioh Studien und Mangement GbR
Verified postcode
Cologne, Germany· Recruiting
Gemeinschaftspraxis Haematologie - Onkologie
Verified postcode
Dresden, Germany· Recruiting

Common questions

What are neuroendocrine tumours (NETs)?

NETs are a type of cancer that can develop in different parts of the body, including the pancreas, gut, and lungs. They are called 'neuroendocrine' because they share features of both nerve cells and hormone-producing cells.

What is cabozantinib?

Cabozantinib is a medicine used to treat certain types of cancer. It works by blocking specific signals within cancer cells that help them grow and spread.

Will I receive new treatment in this study?

No, you will be taking cabozantinib as part of your usual care, as decided by your doctor. The study just collects information about how it works for you.

Will I have extra tests if I join?

No, this is an observational study. Doctors will only collect information from tests and scans you'd have as part of your regular medical care.

Can I stop being part of the study anytime?

Yes, you can choose to leave the study at any time without it affecting your medical treatment or care.

How to find out more

Ipsen Clinical Study Enquiries

clinical.trials@ipsen.com See e mail Official trial record

Always speak to your GP or specialist before deciding to take part in a study.